Current Progress and Challenges in the Study of Adjuvants for Oral Vaccines

Overview

Journal BioDrugs

Specialties Allergy & Immunology
Genetics
Pharmacology

Date 2023 Jan 6

PMID 36607488

Authors

Bingming Ou

Ying Yang

Haihui Lv

Xin Lin

Minyu Zhang

Affiliations

Soon will be listed here.

Abstract

Over the past 20 years, a variety of potential adjuvants have been studied to enhance the effect of oral vaccines in the intestinal mucosal immune system; however, no licensed adjuvant for clinical application in oral vaccines is available. In this review, we systematically updated the research progress of oral vaccine adjuvants over the past 2 decades, including biogenic adjuvants, non-biogenic adjuvants, and their multi-type composite adjuvant materials, and introduced their immune mechanisms of adjuvanticity, aiming at providing theoretical basis for developing feasible and effective adjuvants for oral vaccines. Based on these insights, we briefly discussed the challenges in the development of oral vaccine adjuvants and prospects for their future development.

Citing Articles

Navigating Fish Immunity: Focus on Mucosal Immunity and the Evolving Landscape of Mucosal Vaccines.

Hopo M, Mabrok M, Abu-Elala N, Yu Y Biology (Basel). 2025; 13(12.

PMID: 39765647 PMC: 11727089. DOI: 10.3390/biology13120980.

Progress and prospect of polysaccharides as adjuvants in vaccine development.

Liang X, Zhou J, Wang M, Wang J, Song H, Xu Y Virulence. 2024; 15(1):2435373.

PMID: 39601191 PMC: 11622597. DOI: 10.1080/21505594.2024.2435373.

Analysis of research trends and hotspots in the primary treatment of end-stage renal disease.

Shi L, Wang J, Wei T, Liang Z, Zhang L, Li C Int Urol Nephrol. 2024; .

PMID: 39589637 DOI: 10.1007/s11255-024-04290-4.

oral immunization in mice using multi-antigen of the African swine fever virus elicits a robust immune response.

Gao S, Zuo W, Kang C, Zou Z, Zhang K, Qiu J Front Immunol. 2024; 15:1373656.

PMID: 38742108 PMC: 11089227. DOI: 10.3389/fimmu.2024.1373656.

Layered Double Hydroxides: Recent Progress and Promising Perspectives Toward Biomedical Applications.

Li L, Soyhan I, Warszawik E, van Rijn P Adv Sci (Weinh). 2024; 11(20):e2306035.

PMID: 38501901 PMC: 11132086. DOI: 10.1002/advs.202306035.

References

Vilander A, Dean G . Adjuvant Strategies for Lactic Acid Bacterial Mucosal Vaccines. Vaccines (Basel). 2019; 7(4). PMC: 6963626. DOI: 10.3390/vaccines7040150. View

Li J, Li X, Ma H, Ren X, Hao G, Zhang H . Efficient mucosal vaccination of a novel classical swine fever virus E2-Fc fusion protein mediated by neonatal Fc receptor. Vaccine. 2020; 38(29):4574-4583. DOI: 10.1016/j.vaccine.2020.05.013. View

Onuigbo E, Iseghohimhen J, Chah K, Gyang M, Attama A . Chitosan/alginate microparticles for the oral delivery of fowl typhoid vaccine: Innate and acquired immunity. Vaccine. 2018; 36(33):4973-4978. DOI: 10.1016/j.vaccine.2018.05.087. View

Islam M, Firdous J, Badruddoza A, Reesor E, Azad M, Hasan A . M cell targeting engineered biomaterials for effective vaccination. Biomaterials. 2018; 192:75-94. DOI: 10.1016/j.biomaterials.2018.10.041. View

Kim S, Doh H, Jang M, Ha Y, Chung S, Park H . Oral immunization with Helicobacter pylori-loaded poly(D, L-lactide-co-glycolide) nanoparticles. Helicobacter. 1999; 4(1):33-9. DOI: 10.1046/j.1523-5378.1999.09046.x. View

Carpentier A . [Cancer immunotherapy with CpG-ODN]. Med Sci (Paris). 2005; 21(1):73-7. DOI: 10.1051/medsci/200521173. View

Derrick J, Urwin R, Suker J, Feavers I, Maiden M . Structural and evolutionary inference from molecular variation in Neisseria porins. Infect Immun. 1999; 67(5):2406-13. PMC: 115985. DOI: 10.1128/IAI.67.5.2406-2413.1999. View

Ghadi A, Mahjoub S, Tabandeh F, Talebnia F . Synthesis and optimization of chitosan nanoparticles: Potential applications in nanomedicine and biomedical engineering. Caspian J Intern Med. 2014; 5(3):156-61. PMC: 4143737. View

Yu X, Wen T, Cao P, Shan L, Li L . Alginate-chitosan coated layered double hydroxide nanocomposites for enhanced oral vaccine delivery. J Colloid Interface Sci. 2019; 556:258-265. DOI: 10.1016/j.jcis.2019.08.027. View

10.

Summerton N, Welch R, Bondoc L, Yang H, Pleune B, Ramachandran N . Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine. 2009; 28(5):1404-11. PMC: 2814929. DOI: 10.1016/j.vaccine.2009.10.147. View

11.

Jiang T, Singh B, Li H, Kim Y, Kang S, Nah J . Targeted oral delivery of BmpB vaccine using porous PLGA microparticles coated with M cell homing peptide-coupled chitosan. Biomaterials. 2013; 35(7):2365-73. DOI: 10.1016/j.biomaterials.2013.11.073. View

12.

Czajkowsky D, Hu J, Shao Z, Pleass R . Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med. 2012; 4(10):1015-28. PMC: 3491832. DOI: 10.1002/emmm.201201379. View

13.

Davitt C, Longet S, Albutti A, Aversa V, Nordqvist S, Hackett B . Alpha-galactosylceramide enhances mucosal immunity to oral whole-cell cholera vaccines. Mucosal Immunol. 2019; 12(4):1055-1064. PMC: 7746523. DOI: 10.1038/s41385-019-0159-z. View

14.

Pereira V, Saraiva T, Souza B, Zurita-Turk M, Azevedo M, de Castro C . Development of a new DNA vaccine based on mycobacterial ESAT-6 antigen delivered by recombinant invasive Lactococcus lactis FnBPA+. Appl Microbiol Biotechnol. 2014; 99(4):1817-26. DOI: 10.1007/s00253-014-6285-3. View

15.

Newsted D, Fallahi F, Golshani A, Azizi A . Advances and challenges in mucosal adjuvant technology. Vaccine. 2015; 33(21):2399-405. DOI: 10.1016/j.vaccine.2015.03.096. View

16.

Tovey M, Lallemand C . Adjuvant activity of cytokines. Methods Mol Biol. 2010; 626:287-309. DOI: 10.1007/978-1-60761-585-9_19. View

17.

McGonigle P, Ruggeri B . Animal models of human disease: challenges in enabling translation. Biochem Pharmacol. 2013; 87(1):162-71. DOI: 10.1016/j.bcp.2013.08.006. View

18.

Quintana I, Espariz M, Villar S, Gonzalez F, Pacini M, Cabrera G . Genetic Engineering of Co-producing Antigen and the Mucosal Adjuvant 3' 5'- cyclic di Adenosine Monophosphate (c-di-AMP) as a Design Strategy to Develop a Mucosal Vaccine Prototype. Front Microbiol. 2018; 9:2100. PMC: 6143824. DOI: 10.3389/fmicb.2018.02100. View

19.

Carter D, Reed S . Role of adjuvants in modeling the immune response. Curr Opin HIV AIDS. 2010; 5(5):409-13. PMC: 3894736. DOI: 10.1097/COH.0b013e32833d2cdb. View

20.

Lycke N, Lebrero-Fernandez C . ADP-ribosylating enterotoxins as vaccine adjuvants. Curr Opin Pharmacol. 2018; 41:42-51. DOI: 10.1016/j.coph.2018.03.015. View